Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, will receive the 2023 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research.
Bateman has been chosen to receive the honor for his groundbreaking work in Alzheimer’s research, including the development of plasma biomarkers in Alzheimer’s diagnostics. He will receive the award in October at the Clinical Trials on Alzheimer’s Disease conference in Boston.
Bateman and his team investigate the causes of Alzheimer’s and develop diagnostic measures to help detect the disease before symptoms begin. His team has developed blood tests that are at least 95% accurate at identifying people with Alzheimer’s.
He is the director of the Dominantly Inherited Alzheimer Network (DIAN), where his research has identified a cascade of events and symptoms that could be used to diagnose Alzheimer’s before the onset of symptoms. He is also director of the DIAN Trials Unit, a clinical trials platform that has advanced drug therapeutics to target prevention and progression of the disease. Bateman also co-founded C2N Diagnostics, a biotechnology company that is active in therapeutic and diagnostic developments in neurodegenerative diseases; C2N developed a blood test for Alzheimer’s that is available to doctors and patients.